Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma. Issue 12 (14th November 2018)

• Record Type: Journal Article
• Authors: Ko, Hui‐Hsin; Peng, Hsin‐Hui; Cheng, Shih‐Jung; Kuo, Mark Yen‐Ping
• Is Part Of: Head & neck. Volume 40:Issue 12(2018)
• Page Start: 2642
• Page End: 2647
• Publication Date: 2018-11-14
• Subjects: AKR1B10 -- areca quid -- oral squamous cell carcinoma -- prognosis -- saliva; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25370
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Aldo‐keto reductase family 1 member B10 (AKR1B10) expression in oral squamous cell carcinoma (OSCC) tissue specimens is correlated with the progression and prognosis of OSCC. Methods: Saliva samples were obtained from 35 normal controls and 86 patients with OSCC before cancer surgery. The AKR1B10 levels were determined using enzyme‐linked immunosorbent assay (ELISA). Results: The mean salivary AKR1B10 levels were significantly higher in the patients with OSCC than in the normal controls ( P < .001). Higher salivary AKR1B10 levels were significantly associated with larger tumor size, more advanced clinical stage, and areca quid chewing habit. Patients with OSCC with a higher salivary AKR1B10 level (>646 pg/mL) had a significantly poorer survival than those with a lower (≤646 pg/mL) salivary AKR1B10 level ( P = .026). Conclusion: The salivary AKR1B10 level may be a promising biomarker for screening high‐risk patients with OSCC and monitoring the progression of OSCC.